Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSTA1 added to temozolomide for newly diagnosed glioblastoma
2023-506813-23-00Phase 2Authorised
- Sponsor
- Tartu University Hospital
- Start
- Dec 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing LSTA1 + temozolomide with Placebo + temozolomide (2 arms). Primary endpoint: Overall survival. Planned start Dec 2023; status: authorised.
02
Drugs
certepetide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-506813-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506813-23-00.